Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor

被引：5
|
作者：
Gasparetto, Marco [1 ,2 ]
Burgess, Natasha [1 ]
Naik, Sandhia [1 ,2 ]
Studart, Dominic [1 ]
Kadir, Ahmed [1 ]
Croft, Nick [1 ,2 ]
Sanderson, Ian [2 ]
Deb, Protima [1 ,2 ]
机构：
[1] Royal London Childrens Hosp, Barts Hlth NHS Trust, Dept Paediat Gastroenterol, Level 8 North Tower, London E1 1FR, England
[2] Queen Mary Univ London, Blizard Inst, Barts & London, 4 Newark St, London E1 2AT, England
来源：
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION | 2022年 / 74卷 / 04期
关键词：
anti-tumour necrosis factor; inflammatory bowel disease; proactive; reactive; therapeutic drug monitoring; INFLIXIMAB; OUTCOMES;
D O I：
10.1097/MPG.0000000000003389
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Few studies have addressed whether proactive therapeutic drug monitoring (TDM) results in improved clinical outcomes in children with inflammatory bowel disease (IBD) treated with anti-tumour necrosis factor. The aim of this study was to investigate the impact of using proactive TDM in this patient group. Pilot single-centre observational study to accrue data on patients managed with proactive TDM. More patients in the proactive TDM cohort were managed by escalating the infliximab (IFX) regime (P < 0.001). The need for switching to different biologics was significantly lower in this patient group (P < 0.001). The introduction of proactive TDM resulted in a significant reduction of patients requiring switch of their primary biologic. The results of this study are indicators that proactive TDM offers a better method of managing children with IBD on IFX therapy.
引用
收藏
页码：484 / 489
页数：6
相关论文
共 50 条
  • [1] Therapeutic drug monitoring of anti-tumour necrosis factor-a agents in inflammatory bowel disease
    Mitrev, Nikola
    Leong, Rupert W.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 303 - 317
  • [2] A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease
    Thomas, Pepijn W. A.
    Chin, Paul K. L.
    Barclay, Murray L.
    INTERNAL MEDICINE JOURNAL, 2021, 51 (03) : 341 - 347
  • [3] Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements
    Maria Giraldez-Montero, Jose
    Gonzalez-Lopez, Jaime
    Campos-Toimil, Manuel
    Jesus Lamas-Diaz, Maria
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (05) : 2216 - 2227
  • [4] ANTI-TUMOUR NECROSIS FACTOR-ALFA DRUG MONITORING IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE
    Muhammed, R.
    Wong, T.
    Haller, W.
    Bremner, R.
    Protheroe, S.
    GUT, 2015, 64 : A432 - A433
  • [5] Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still Out
    Agrawal, Manasi
    Dubinsky, Marla C.
    Colombela, Jean-Frederic
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (08): : 1035 - 1036
  • [6] Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
    Mitrev, N.
    Vande Casteele, N.
    Seow, C. H.
    Andrews, J. M.
    Connor, S. J.
    Moore, G. T.
    Barclay, M.
    Begun, J.
    Bryant, R.
    Chan, W.
    Corte, C.
    Ghaly, S.
    Lemberg, D. A.
    Kariyawasam, V.
    Lewindon, P.
    Martin, J.
    Mountifield, R.
    Radford-Smith, G.
    Slobodian, P.
    Sparrow, M.
    Toong, C.
    van Langenberg, D.
    Ward, M. G.
    Leong, R. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (11-12) : 1037 - 1053
  • [7] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Konstantinos Papamichael
    Severine Vermeire
    World Journal of Gastroenterology, 2015, (16) : 4773 - 4778
  • [8] Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease
    Papamichael, Konstantinos
    Vermeire, Severine
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (16) : 4773 - 4778
  • [9] Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    GASTROENTEROLOGY, 2019, 157 (04) : 922 - 924
  • [10] Clinical impact of routine anti-Tumour Necrosis Factor (anti-TNF) therapeutic drug monitoring (TDM) in the management of Inflammatory Bowel Disease (IBD) patients
    Guirgis, M.
    Bianchetti, D.
    Dorta, G.
    Michetti, P.
    Maillard, M.
    SWISS MEDICAL WEEKLY, 2015, 145 : S3 - S3
12345